11 results for 'Molmed'
A statistically significant 40% improvement of both overall survival and progression-free survival in a large population of patients, identified by a pre-specified analysis on the prior treatment-free interval, and who presented a very dismal prognosis was reported by MolMed S.p.A. (MLM.MI) this weekend, at the 50th ASCO annual meeting.
These efficacy results were observed in an international randomized Phase III study evaluating the investigational drug NGR-hTNF in combination with best investigator choice in 400 patients with malignant pleural mesothelioma (MPM) who had previously... (more)
MolMed S.p.A. (MLM.MI) provided at the 50th ASCO annual meeting new data from the ongoing randomised pivotal Phase III study on its cell therapy product TK for high-risk acute leukaemia patients transplanted from partially matched (haplo-identical) donors.
The intent-to-treat analysis of the first 24 patients treated with TK indicates a 74% 1-year disease free survival (DFS) as the primary study endpoint: this result largely exceeds the target of 52% DSF for the TK arm vs 30% for the control arm.
Notably, 86% of patients treated with TK were alive at one year (the key secondary... (more)
MolMed S.p.A. (MLM.MI) today announced the results of the double-blinded, placebo-controlled Phase III trial of NGR-hTNF versus best investigator choice in 400 patients with malignant pleural mesothelioma who had previously failed a first-line chemotherapy.
Despite not meeting its primary endpoint of improving overall survival (OS) in the entire population, the study showed a statistically significant (unstratified p=0.02; stratified p=0.01) 40% improvement of OS in patients with poorer prognosis who had progressed during or shortly after first-line chemotherapy. These patients represent... (more)
TK is an adjunctive treatment in hematopoietic stem cell transplantation for patients affected by high risk leukaemia. TK has been granted orphan drug status by the European Commission.
MolMed is also glad to announce that the Company has been invited by the European Society for Blood and Marrow Transplantation (EMBT) to illustrate the scientific and regulatory path of TK which – with more than 120 patients treated so far – is the largest cell-gene therapy application ever performed. Claudio Bordignon, CEO and president of the Board, will give a presentation on the topic next Tuesday... (more)
It is estimated that in EU approximately 5,000 leukaemia patients/year lack a fully compatible donor: TK offers to these patients the option of transplantation from a mismatched donor without post-transplant immunosuppression. If approved, TK would be the first cell-gene therapy product on the market for this life threatening condition. The Conditional Marketing Authorisation application is supported by cumulative efficacy and safety results obtained from a completed Phase I-II, multicentre trial (TK007). These data were included in presentations given at the 49th annual congress... (more)
The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues to € 3.1 million from development of new cell and gene therapy treatments for third parties.
Milan (Italy), 11 November 2013 – The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today... (more)
The study, already ongoing in Europe, foresees patient enrolment in 16 clinical centres worldwide. Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: “The treatment with TK cells of this first US patient opens new frontiers to the dissemination of MolMed’s technology”.
MolMed S.p.A. (MLM.MI) announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial (TK008) of its proprietary TK
cell/gene therapy for high-risk leukaemia patients.
The study, already ongoing in Europe, foresees... (more)
MolMed, new data presented at the European Cancer Congress show a statistically significant increase in survival of patients suffering from soft tissue sarcomas treated with NGR-hTNF.
MolMed S.p.A. (MLM.MI) presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), in Amsterdam (The Netherlands), additional data from an ongoing randomized Phase II study evaluating safety and efficacy of its investigational drug NGR-hTNF on patients suffering from soft tissue sarcomas. Data show the impact of the weekly administration of NGR-hTNF at low doses (0,8?g/sqm) in combination... (more)
MolMed S.p.A. (MLM.MI) will present further data on the efficacy of its investigational drug NGR-hTNF in combination with doxorubicin in soft tissue sarcomas, tomorrow at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) taking place in Amsterdam (The Netherlands) from September 27th to October 1st 2013.
Dr Emanuela Palmerini from the Istituto ortopedico Rizzoli (Bologna) will give an oral presentation titled “NGR-hTNF given at low dose or high dose with or without doxorubicin in soft-tissue sarcomas” at 9:12 of Tuesday, October the 1st 2013 in the section “Sarcomas: soft tissues and... (more)
MolMed Shareholders’ Meeting confirms the appointment of a Member of the Board and approves Measures to be adopted pursuant to Article 2446 of the Italian Civil Code. Meeting of the Board of Directors: Professor Riccardo Cortese appointed as member of the Remuneration committee.
The Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, met today to resolve upon the items of the agenda.
Item 1 of the Ordinary part: proposal of confirmation of a Member of the Board of Directors, appointed pursuant to Article... (more)